Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | January 04, 2021 | January 06, 2021 |
| ImmunityBio, Inc.IBRX · Entity 3618 | Director | October 05, 2026 | October 06, 2026 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | Director | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date January 04, 2021 · Filed January 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.36 · Expires 2031-01-03 | Direct | 10,000 |
Reported balance
After 2021-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-04 · Grant · Acquired 10,000 · Balance 10,000 F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date.
ImmunityBio, Inc.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,777,788 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Sale · Disposed 25,000 · Balance 2,777,788 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025. F2: Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $10.665 to $10.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.
F2: Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $10.665 to $10.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Viracta Therapeutics, Inc.
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2034-06-20 | Direct | 50,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 50,000 · Balance 50,000 F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2020 Filed Dec 28, 2020 23:23 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 130,000 | $2.00 | $259,792.00 |
DisclosureSEC source: 0001209191-20-065246 · doc4.xml · nonDerivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 1,565 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043298 · doc4.xml · derivative · entry 8 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,120 Underlying: Common Stock · 1,565 shares Expires 2025-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is January 16, 2015. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 1,565 | $15.50 | $24,258.13 |
DisclosureSEC source: 0001209191-20-043298 · doc4.xml · nonDerivative · entry 5 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,540 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F3 · price: Represents the weighted average share price of an aggregate total of 1,565 shares sold in the price range of $15.50 to $15.5050 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 1,565 | $2.00 | $3,127.50 |
DisclosureSEC source: 0001209191-20-043298 · doc4.xml · nonDerivative · entry 4 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,172,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 87,705 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043298 · doc4.xml · derivative · entry 7 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,685 Underlying: Common Stock · 87,705 shares Expires 2025-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is January 16, 2015. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 40,730 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-20-043298 · doc4.xml · derivative · entry 6 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,967 Underlying: Common Stock · 40,730 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is December 18, 2014. The option originally covered 200,000 pre 1.8515 for 1 forward split shares. Pursuant to the reporting person's employment agreement, the shares subject to the option shall be subject to certain accelerated vesting and post-termination exercise period provisions upon certain events. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 128,435 | $15.53 | $1,995,070.76 |
DisclosureSEC source: 0001209191-20-043298 · doc4.xml · nonDerivative · entry 3 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,540 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F2 · price: Represents the weighted average share price of an aggregate total of 128,435 shares sold in the price range of $15.50 to $15.70 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 87,705 | $2.00 | $175,269.67 |
DisclosureSEC source: 0001209191-20-043298 · doc4.xml · nonDerivative · entry 2 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,298,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:05 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 40,730 | $1.76 | $71,497.44 |
DisclosureSEC source: 0001209191-20-043298 · doc4.xml · nonDerivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,211,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 21:00 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 39,950 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-20-042183 · doc4.xml · derivative · entry 3 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,697 Underlying: Common Stock · 39,950 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is December 18, 2014. The option originally covered 200,000 pre 1.8515 for 1 forward split shares. Pursuant to the reporting person's employment agreement, the shares subject to the option shall be subject to certain accelerated vesting and post-termination exercise period provisions upon certain events. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 21:00 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 39,950 | $13.14 | $524,759.23 |
DisclosureSEC source: 0001209191-20-042183 · doc4.xml · nonDerivative · entry 2 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,540 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F2 · price: Represents the weighted average share price of an aggregate total of 39,950 shares sold in the price range of $13.00 to $13.29 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 21:00 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 39,950 | $1.76 | $70,128.23 |
DisclosureSEC source: 0001209191-20-042183 · doc4.xml · nonDerivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,210,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 22:32 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 9 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-20-040651 · doc4.xml · derivative · entry 3 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,647 Underlying: Common Stock · 9 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is December 18, 2014. The option originally covered 200,000 pre 1.8515 for 1 forward split shares. Pursuant to the reporting person's employment agreement, the shares subject to the option shall be subject to certain accelerated vesting and post-termination exercise period provisions upon certain events. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 22:32 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 9 | $13.00 | $117.00 |
DisclosureSEC source: 0001209191-20-040651 · doc4.xml · nonDerivative · entry 2 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,540 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 22:32 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 9 | $1.76 | $15.80 |
DisclosureSEC source: 0001209191-20-040651 · doc4.xml · nonDerivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 29,609 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · derivative · entry 11 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,656 Underlying: Common Stock · 29,609 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is December 18, 2014. The option originally covered 200,000 pre 1.8515 for 1 forward split shares. Pursuant to the reporting person's employment agreement, the shares subject to the option shall be subject to certain accelerated vesting and post-termination exercise period provisions upon certain events. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 29,609 | $13.01 | $385,133.15 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · nonDerivative · entry 8 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,540 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F6 · price: Represents the weighted average share price of an aggregate total of 29,609 shares sold in the price range of $13.00 to $13.04 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 29,609 | $1.76 | $51,975.64 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · nonDerivative · entry 7 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 136,729 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · derivative · entry 10 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,265 Underlying: Common Stock · 136,729 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is December 18, 2014. The option originally covered 200,000 pre 1.8515 for 1 forward split shares. Pursuant to the reporting person's employment agreement, the shares subject to the option shall be subject to certain accelerated vesting and post-termination exercise period provisions upon certain events. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 10,432 | $13.01 | $135,708.84 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · nonDerivative · entry 6 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,170,540 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F5 · price: Represents the weighted average share price of an aggregate total of 10,432 shares sold in the price range of $13.00 to $13.10 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 80,000 | $10.55 | $843,664.00 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · nonDerivative · entry 5 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,180,972 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F4 · price: Represents the weighted average share price of an aggregate total of 80,000 shares sold in the price range of $10.50 to $10.88 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 66,263 | $9.43 | $624,807.08 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · nonDerivative · entry 4 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,260,972 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F3 · price: Represents the weighted average share price of an aggregate total of 66,263 shares sold in the price range of $9.25 to $9.71 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 136,729 | $1.76 | $240,014.09 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · nonDerivative · entry 3 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 9,337 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · derivative · entry 9 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,994 Underlying: Common Stock · 9,337 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is December 18, 2014. The option originally covered 200,000 pre 1.8515 for 1 forward split shares. Pursuant to the reporting person's employment agreement, the shares subject to the option shall be subject to certain accelerated vesting and post-termination exercise period provisions upon certain events. Read SEC document |
| June 19, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 13,737 | $9.00 | $123,637.12 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · nonDerivative · entry 2 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,190,506 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F2 · price: Represents the weighted average share price of an aggregate total of 13,737 shares sold in the price range of $9.00 to $9.02 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 19, 2020 Filed Jun 24, 2020 01:45 UTC | ImmunityBio, Inc. NK · Entity 3618 | Exercise / conversionCommon Stock | 9,337 | $1.76 | $16,390.17 |
DisclosureSEC source: 0001209191-20-038679 · doc4.xml · nonDerivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,204,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:27 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 75,000 | $7.56 | $567,337.50 |
DisclosureSEC source: 0001209191-20-032930 · doc4.xml · nonDerivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,194,906 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F2 · price: Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $7.50 to $7.645 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 21, 2020 Filed May 22, 2020 21:37 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 36,932 | $5.52 | $203,698.45 |
DisclosureSEC source: 0001209191-20-031845 · doc4.xml · nonDerivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,269,906 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F2 · price: Represents the weighted average share price of an aggregate total of 36,932 shares sold in the price range of $5.50 to $5.555 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2020 Filed May 14, 2020 00:04 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 28,068 | $5.50 | $154,508.73 |
DisclosureSEC source: 0001209191-20-029014 · doc4.xml · nonDerivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,306,838 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 12, 2019. F2 · price: Represents the weighted average share price of an aggregate total of 28,068 shares sold in the price range of $5.50 to $5.5350 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:02 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 9,600 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002066 · doc4.xml · derivative · entry 1 Simon Barry J. · CIK 0001647994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:40 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 9,600 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001336 · doc4.xml · derivative · entry 1 Simon Barry J. · CIK 0001647994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2026-01-02 Read SEC document |
| August 27, 2018 Filed Aug 30, 2018 01:00 UTC | ImmunityBio, Inc. NK · Entity 3618 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001209191-18-048878 · doc4.xml · derivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-08-27 F1 · derivative.exercise_date: Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:39 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037818 · doc4.xml · derivative · entry 1 Simon Barry J. · CIK 0001647994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2016 Filed Sep 9, 2016 22:40 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 30,000 | $7.40 | $222,000.00 |
DisclosureSEC source: 0001209191-16-140825 · doc4.xml · nonDerivative · entry 2 Simon Barry J. · CIK 0001647994 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334,906 Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 22:40 UTC | ImmunityBio, Inc. NK · Entity 3618 | SaleCommon Stock | 2,000 | $8.84 | $17,671.20 |
DisclosureSEC source: 0001209191-16-140825 · doc4.xml · nonDerivative · entry 1 Simon Barry J. · CIK 0001647994 · Director · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · By mother-in-law Disclosed balance after: 21,143 F1 · price: Represents the weighted average share price of an aggregate total of 400 shares sold in the price range of $60.00 to $60.01 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.